Cocquyt V - Search Results

1

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Kruse V, Denys H, Van Den Broecke R, Van Belle S, Cocquyt V. Kruse V, et al. Among authors: cocquyt v. Springerplus. 2013 May 1;2(1):202. doi: 10.1186/2193-1801-2-202. Print 2013 Dec. Springerplus. 2013. PMID: 23710429 Free PMC article.

2

Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy.

Van Belle SJ, Cocquyt V. Van Belle SJ, et al. Among authors: cocquyt v. Crit Rev Oncol Hematol. 2003 Jul;47(1):1-11. doi: 10.1016/s1040-8428(03)00093-3. Crit Rev Oncol Hematol. 2003. PMID: 12853095 Review.

3

Lobular carcinoma in situ and invasive lobular cancer of the breast.

Cocquyt V, Van Belle S. Cocquyt V, et al. Curr Opin Obstet Gynecol. 2005 Feb;17(1):55-60. doi: 10.1097/00001703-200502000-00010. Curr Opin Obstet Gynecol. 2005. PMID: 15711412 Review.

4

Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.

Van Belle SJ, Cocquyt V. Van Belle SJ, et al. Among authors: cocquyt v. Expert Opin Pharmacother. 2008 Dec;9(18):3261-70. doi: 10.1517/14656560802548463. Expert Opin Pharmacother. 2008. PMID: 19040346 Review.

5

Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer.

Hendrix A, Sormunen R, Westbroek W, Lambein K, Denys H, Sys G, Braems G, Van den Broecke R, Cocquyt V, Gespach C, Bracke M, De Wever O. Hendrix A, et al. Among authors: cocquyt v. Int J Cancer. 2013 Aug 15;133(4):843-54. doi: 10.1002/ijc.28079. Epub 2013 Mar 7. Int J Cancer. 2013. PMID: 23390068

6

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.

Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V. Marlier J, et al. Among authors: cocquyt v. Endocrine. 2014 Dec;47(3):878-83. doi: 10.1007/s12020-014-0199-9. Epub 2014 Feb 21. Endocrine. 2014. PMID: 24554495

7

Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer.

Kruse V, VAN DE Wiele C, Maes A, Borms M, Pottel H, VAN Belle S, Cocquyt V. Kruse V, et al. Among authors: cocquyt v. Q J Nucl Med Mol Imaging. 2017 Mar;61(1):108-114. doi: 10.23736/S1824-4785.16.02727-8. Epub 2014 Oct 7. Q J Nucl Med Mol Imaging. 2017. PMID: 25289633

8

Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature.

Vertriest C, Berardi G, Tomassini F, Vanden Broucke R, Depypere H, Cocquyt V, Denys H, Van Belle S, Troisi RI. Vertriest C, et al. Among authors: cocquyt v. Dig Surg. 2015;32(1):52-9. doi: 10.1159/000375132. Epub 2015 Feb 11. Dig Surg. 2015. PMID: 25675843 Review.

9

Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L. Lambein K, et al. Among authors: cocquyt v. Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31. Virchows Arch. 2017. PMID: 28567637

10

The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer.

Cocquyt VF, Schelfhout VR, Blondeel PN, Depypere HT, Daems KK, Serreyn RF, Praet MM, Van Belle SJ. Cocquyt VF, et al. Med Oncol. 2003;20(3):221-31. doi: 10.1385/mo:20:3:221. Med Oncol. 2003. PMID: 14514971

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters